# Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

> **NCT01866319** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 834 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT01866319
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-28
- **Primary completion:** 2015-03-03
- **Final completion:** 2019-06-03
- **Target enrollment:** 834 (ACTUAL)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01866319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01866319, "Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01866319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*